BCBrian S. Comer

Brian S. Comer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brian S. Comer has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • William T. Gerthoffer

    Department of Biochemistry and Molecular Biology, University of South Alabama, Mobile, Alabama

    6 shared publications
  • Andrew J. Halayko

    Departments of Physiology and Pathophysiology, and Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; and

    2 shared publications
  • Blanca Camoretti-Mercado

    Center for Personalized Medicine and Genomics, Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida College of Medicine, Tampa, Florida

    2 shared publications
  • Jared Milligan McLendon

    Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, United States; Abboud Cardiovascular Research Center, University of Iowa, Iowa City, IA, United States

    2 shared publications
  • Julian Solway

    Department of Medicine and

    2 shared publications
  • Paul C. Kogut

    Department of Medicine and

    2 shared publications

Latest Publications

  • Efficacious psoriasis treatment improves patients' work productivity

    by J.J. Wu, C.‐Y. Lin, O. Goldblum, A. Zbrozek, B.S. Comer, R. Burge, M. Augustin, S.R. Feldman

    Recently, Wu and colleagues reported that an absolute improvement of 20% represented a minimal clinically important difference (MCID) for the work productivity loss and activity impairment domains of the Work Productivity and Activity Impairment Questionnaire for Psoriasis (WPAI:PsO).1 We evaluated whether there were meaningful improvements in work productivity with etanercept and ixekizumab treatment. Data were obtained from clinical trials comparing etanercept, ixekizumab, and placebo for adults with moderate‐to‐severe plaque psoriasis, as described previously. Patients were randomized to PBO, 80‐mg ixekizumab every 2 weeks (IXEQ2W), 80‐mg ixekizumab every 4 weeks (IXEQ4W), or etanercept 50‐mg twice weekly for 12 weeks. Patients treated with ixekizumab received a 160‐mg starting dose.


  • Open Access

    Nanoparticle Delivery of Anti-inflammatory LNA Oligonucleotides Prevents Airway Inflammation in a HDM Model of Asthma

    by Sabrina C. Ramelli, Brian S. Comer, Jared M. McLendon, Lydia L. Sandy, Andrew P. Ferretti, Robert Barrington, Jeff Sparks, Majed Matar, Jason Fewell, William T. Gerthoffer


  • Open Access

    Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization

    by April W. Armstrong, Shonda A. Foster, Brian S. Comer, Chen-Yen Lin, William Malatestinic, Russel Burge, Orin Goldblum

    Little is known regarding real-world health outcomes data among US psoriasis patients, but electronic health records (EHR) that collect structured data at point-of-care may provide opportunities to investigate real-world health outcomes among psoriasis patients. Our objective was to investigate patient-perceived treatment effectiveness, patterns of medication use (duration, switching, and/or discontinuation), healthcare resource utilization, and medication costs using real-world data from psoriasis patients. Data for adults (≥18-years) with a dermatology provider-given diagnosis of psoriasis from 9/2014–9/2015 were obtained from dermatology practices using a widely used US dermatology-specific EHR containing over 500,000 psoriasis patients. Disease severity was captured by static physician’s global assessment and body surface area. Patient-perceived treatment effectiveness was assessed by a pre-defined question. Treatment switching and duration were documented. Reasons for discontinuations were assessed using pre-defined selections. Healthcare resource utilization was defined by visit frequency and complexity. From 82,621 patients with psoriasis during the study period, patient-perceived treatment effectiveness was investigated in 2200 patients. The proportion of patients reporting “strongly agree” when asked if their treatment was effective was highest for biologics (73%) and those reporting treatment adherence (55%). In 16,000 patients who received oral systemics and 21,087 patients who received biologics, median treatment duration was longer for those who received biologics (160 vs. 113 days, respectively). Treatment switching was less frequent among patients on systemic monotherapies compared to those on combination therapies. The most common reason for discontinuing biologics was loss of efficacy; the most common reason for discontinuing orals was side effects. In 28,754 patients, higher disease severity was associated with increased healthcare resource utilization (increased visit frequency and complexity). When compared between treatment groups (n = 10,454), healthcare resource utilization was highest for phototherapy. Annual medication costs were higher for biologics ($21,977) than oral systemics ($3413). Real-world research using a widely implemented dermatology EHR provided valuable insights on patient perceived treatment effectiveness, patterns of medication usage, healthcare resource utilization, and medication costs for psoriasis patients in the US. This study and others utilizing EHRs for real-world research may assist clinical and payer decisions regarding the management of psoriasis.


  • Endothelial SK3 channel-associated Ca2+ microdomains modulate blood pressure

    by Fui C. Yap, David S. Weber, Mark S. Taylor, Mary I. Townsley, Brian S. Comer, James Maylie, John P. Adelman, Mike T. Lin

    Activation of vascular endothelial small- (KCa2.3, SK3) or intermediate- (KCa3.1, IK1) conductance Ca2+-activated potassium channels induces vasorelaxation via an endothelium-derived hyperpolarization (EDH) pathway. Although the activation of SK3 and IK1 channels converges on EDH, their subcellular effects on signal transduction are different and not completely clear. In this study, a novel endothelium-specific SK3 knockout (SK3−/−) mouse model was utilized to specifically examine the contribution of SK3 channels to mesenteric artery vasorelaxation, endothelial Ca2+ dynamics, and blood pressure. The absence of SK3 expression was confirmed using real-time quantitative PCR and Western blot analysis. Functional studies showed impaired EDH-mediated vasorelaxation in SK3−/− small mesenteric arteries. Immunostaining results from SK3−/− vessels confirmed the absence of SK3 and further showed altered distribution of transient receptor potential channels, type 4 (TRPV4). Electrophysiological recordings showed a lack of SK3 channel activity, while TRPV4-IK1 channel coupling remained intact in SK3−/− endothelial cells. Moreover, Ca2+ imaging studies in SK3−/− endothelium showed increased Ca2+ transients with reduced amplitude and duration under basal conditions. Importantly, SK3−/− endothelium lacked a distinct type of Ca2+ dynamic that is sensitive to TRPV4 activation. Blood pressure measurements showed that the SK3−/− mice were hypertensive, and the blood pressure increase was further enhanced during the 12-h dark cycle when animals are most active. Taken together, our results reveal a previously unappreciated SK3 signaling microdomain that modulates endothelial Ca2+ dynamics, vascular tone, and blood pressure.


  • Does miRNA‐155 Promote Cyclooxygenase‐2 Expression in Cancer?

    by Brian S. Comer

    Preclinical Research MicroRNA (miR)‐155 and cyclooxygenase (COX)‐2 are both elevated in numerous cancers including colorectal cancer. MiR‐155 enhances COX‐2 expression and is an established regulator of epithelial‐mesenchymal transition and inflammation. Inhibition of miR‐155 or COX‐2 exhibit similar negative effects on tumorigenicity. Thus, it is hypothesized that miR‐155 may be a promising target for antagonizing COX‐2 expression in colorectal and other cancers.


  • Cyclooxygenase-2 and MicroRNA-155 Expression Are Elevated in Asthmatic Airway Smooth Muscle Cells

    by Brian S. Comer, Blanca Camoretti-Mercado, Paul C. Kogut, Andrew J. Halayko, Julian Solway, William T. Gerthoffer

    Cyclooxygenase-2 (COX-2) expression and PGE2 secretion from human airway smooth muscle cells (hASMCs) may contribute to β2-adrenoceptor hyporesponsiveness, a clinical feature observed in some patients with asthma. hASMCs from patients with asthma exhibit elevated expression of cytokine-responsive genes, and in some instances this is attributable to an altered histone code and/or microRNA expression. We hypothesized that COX-2 expression and PGE2 secretion might be elevated in asthmatic hASMCs in response to proinflammatory signals in part due to altered histone acetylation and/or microRNA expression. hASMCs obtained from nonasthmatic and asthmatic human subjects were treated with cytomix (IL-1β, TNF-α, and IFN-γ). A greater elevation of COX-2 mRNA, COX-2 protein, and PGE2 secretion was observed in the asthmatic cells. We investigated histone H3/H4-acetylation, transcription factor binding, mRNA stability, p38 mitogen-activated protein kinase signaling, and microRNA (miR)-155 expression as potential mechanisms responsible for the differential elevation of COX-2 expression. We found that histone H3/H4-acetylation and transcription factor binding to the COX-2 promoter were similar in both groups, and histone H3/H4-acetylation did not increase after cytomix treatment. Cytomix treatment elevated NF-κB and RNA polymerase II binding to similar levels in both groups. COX-2 mRNA stability was increased in asthmatic cells. MiR-155 expression was higher in cytomix-treated asthmatic cells, and we show it enhances COX-2 expression and PGE2 secretion in asthmatic and nonasthmatic hASMCs. Thus, miR-155 expression positively correlates with COX-2 expression in the asthmatic hASMCs and may contribute to the elevated expression observed in these cells. These findings may explain, at least in part, β2-adrenoceptor hyporesponsiveness in patients with asthma.


  • Epigenetic targets for novel therapies of lung diseases

    by Brian S. Comer, Mariam Ba, Cherie A. Singer, William T. Gerthoffer


  • MicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscle

    by Brian S. Comer, Blanca Camoretti-Mercado, Paul C. Kogut, Andrew J. Halayko, Julian Solway, William T. Gerthoffer

    MicroRNA (miR)-146a and miR-146b are negative regulators of inflammatory gene expression in lung fibroblasts, epithelial cells, monocytes, and endothelial cells. The abundance of cyclooxygenase-2 (COX-2) and IL-1β is negatively regulated by the miR-146 family, suggesting miR-146a and/or miR-146b might modulate inflammatory mediator expression in airway smooth muscle thereby contributing to pathogenesis of asthma. To test this idea we compared miR-146a and miR-146b expression in human airway smooth muscle cells (hASMCs) from nonasthmatic and asthmatic subjects treated with cytomix (IL-1β, TNF-α, and IFNγ) and examined the miRNAs' effects on COX-2 and IL-1β expression. We found that cytomix treatment elevated miR-146a and miR-146b abundance. Induction with cytomix was greater than induction with individual cytokines, and asthmatic cells exhibited higher levels of miR-146a expression following cytomix treatment than nonasthmatic cells. Transfection of miR-146a or miR-146b mimics reduced COX-2 and IL-1β expression. A miR-146a inhibitor increased COX-2 and IL-1β expression, but a miR-146b inhibitor was ineffective. Repression of COX-2 and IL-1β expression by miR-146a correlated with reduced abundance of the RNA-binding protein human antigen R. These results demonstrate that miR-146a and miR-146b expression is inducible in hASMCs by proinflammatory cytokines and that miR-146a expression is greater in asthmatic cells. Both miR-146a and miR-146b can negatively regulate COX-2 and IL-1β expression at pharmacological levels, but loss-of-function studies showed that only miR-146a is an endogenous negative regulator in hASMCs. The results suggest miR-146 mimics may be an attractive candidate for further preclinical studies as an anti-inflammatory treatment of asthma.


    • 1 January 2012
      • Vol. 4  (1) , 1-16

    MicroRNA Regulation of Smooth Muscle Phenotype

    by Sachindra R. Joshi, Brian S. Comer, Jared M. McLendon, William T. Gerthoffer

    Advances in studies of microRNA (miRNA) expression and function in smooth muscles illustrate important effects of small noncoding RNAs on cell proliferation, hypertrophy and differentiation. An emerging theme in miRNA research in a variety of cell types including smooth muscles is that miRNAs regulate protein expression networks to fine tune phenotype. Some widely expressed miRNAs have been described in smooth muscles that regulate important processes in many cell types, such as miR-21 control of proliferation and cell survival. Other miRNAs that are prominent regulators of smooth muscle-restricted gene expression also have targets that control pluripotent cell differentiation. The miR-143~145 cluster which targets myocardin and Kruppel-like factor 4 (KLF4) is arguably the best-described miRNA family in smooth muscles with profound effects on gene expression networks that promote serum response factor (SRF)-dependent contractile and cytoskeletal protein expression and the mature contractile phenotype. Kruppel-family members KLF4 and KLF5 have multiple effects on cell differentiation and are targets for multiple miRNAs in smooth muscles (miR-145, miR-146a, miR-25). The feedback and feedforward loops being defined appear to contribute significantly to vascular and airway remodeling in cardiovascular and respiratory diseases. RNA interference approaches applied to animal models of vascular and respiratory diseases prove that miRNAs and RNA-induced silencing are valid targets for novel anti-remodeling therapies that alter pathological smooth muscle hyperplasia and hypertrophy.


  • Open Access

    MicroRNAs‐Control of Essential Genes: Implications for Pulmonary Vascular Disease

    by Sachindra R. Joshi, Jared M. McLendon, Brian S. Comer, William T. Gerthoffer

    During normal lung development and in lung diseases structural cells in the lungs adapt to permit changes in lung function. Fibroblasts, myofibroblasts, smooth muscle, epithelial cells, and various progenitor cells can all undergo phenotypic modulation. In the pulmonary vasculature occlusive vascular lesions that occur in severe pulmonary arterial hypertension are multifocal, polyclonal lesions containing cells presumed to have undergone phenotypic transition resulting in altered proliferation, cell lifespan or contractility. Dynamic changes in gene expression and protein composition that underlie processes responsible for such cellular plasticity are not fully defined. Advances in molecular biology have shown that multiple classes of ribonucleic acid (RNA) collaborate to establish the set of proteins expressed in a cell. Both coding Messenger Ribonucleic acid (mRNA) and small noncoding RNAs (miRNA) act via multiple parallel signaling pathways to regulate transcription, mRNA processing, mRNA stability, translation and possibly protein lifespan. Rapid progress has been made in describing dynamic features of miRNA expression and miRNA function in some vascular tissues. However posttranscriptional gene silencing by microRNA‐mediated mRNA degradation and translational blockade is not as well defined in the pulmonary vasculature. Recent progress in defining miRNAs that modulate vascular cell phenotypes is reviewed to illustrate both functional and therapeutic significance of small noncoding RNAs in pulmonary arterial hypertension.